We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Optimal Antiplatelet Therapy for Chinese Patients With Coronary Artery Disease (OPT-CAD)

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01735305
First Posted: November 28, 2012
Last Update Posted: December 11, 2015
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborator:
Guangdong General Hospital
Information provided by (Responsible Party):
Han Yaling, Shenyang Northern Hospital
  Purpose
Antiplatelet therapy is the cornerstone for the prevention of atherothrombosis in patients with coronary artery disease (CAD). However, the efficacy and safety of antiplatelet therapy are varied due to ethnic and/or individual variability. The aim of the OPT-CAD study was to demonstrate contemporary status and outcomes of antiplatelet therapy in Chinese CAD patients, and to explore predictors of ischemic or bleeding events in such cohort.Patients above 18 years old who were diagnosed as CAD and received antiplatelet therapy were prospectively enrolled in this national wide, non-intervention registry. All medications and laboratory tests were physician discretion.

Condition
Coronary Artery Disease

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Optimal Antiplatelet Therapy for Chinese Patients With Coronary Artery Disease

Resource links provided by NLM:


Further study details as provided by Han Yaling, Shenyang Northern Hospital:

Primary Outcome Measures:
  • Major adverse cardiac and cerebral events [ Time Frame: 12month ]
    a composite of all cause death, myocardial infarction, stroke or any revascularization or stroke


Secondary Outcome Measures:
  • all cause death [ Time Frame: 12month ]
  • Stent thrombosis [ Time Frame: 12 month ]
    by BARC definition

  • rehospitalization [ Time Frame: 12 month ]
    any rehospitalization for cardiac or noncardiac reasons

  • any bleeding events [ Time Frame: 12 month ]
    by BARC definition

  • recurrent angina [ Time Frame: 12 month ]
  • myocardial infarction [ Time Frame: 12 months ]
  • stroke [ Time Frame: 12 months ]
  • any revascularization [ Time Frame: 12 months ]

Enrollment: 14032
Study Start Date: November 2012
Study Completion Date: March 2015
Primary Completion Date: December 2014 (Final data collection date for primary outcome measure)
Groups/Cohorts
Antiplatelet therapy
patients with coronary artery disease receiving any antiplatelet therapy, without any intervention by the investigators.

Detailed Description:
Antiplatelet therapy is the cornerstone for the prevention of atherothrombosis in patients with coronary artery disease (CAD). However, the efficacy and safety of antiplatelet therapy are varied due to ethnic and/or individual variability. The aim of the OPT-CAD study was to demonstrate contemporary status and outcomes of antiplatelet therapy in Chinese CAD patients, and to explore predictors of ischemic or bleeding events in such cohort.Patients above 18 years who were diagnosed as CAD and received antiplatelet therapy were prospectively enrolled in this national wide, non-intervention registry. All medications and laboratory tests were at physician discretion.
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 85 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Patient of coronary heart disease receiving any antiplatelet therapy
Criteria

Inclusion criteria:

  1. Clinical diagnosis of coronary heart disease
  2. Age >= 18 years old
  3. receiving any antiplatelet agents
  4. Informed written consent signed

Exclusion Criteria:

  1. With severe disease and life expectancy for 6 months or less
  2. Difficult to attain follow-up situations judged by researchers (travel, speech or mental disorder, etc.)
  3. Taking part in an interventional clinical research
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01735305


  Show 107 Study Locations
Sponsors and Collaborators
Shenyang Northern Hospital
Guangdong General Hospital
Investigators
Principal Investigator: Yaling Han, MD Shenyang Military Region General Hospital
  More Information

Responsible Party: Han Yaling, Dr, Shenyang Northern Hospital
ClinicalTrials.gov Identifier: NCT01735305     History of Changes
Other Study ID Numbers: SYNH-20121113
First Submitted: November 12, 2012
First Posted: November 28, 2012
Last Update Posted: December 11, 2015
Last Verified: December 2015

Keywords provided by Han Yaling, Shenyang Northern Hospital:
Coronary Artery Disease
antiplatelet therapy

Additional relevant MeSH terms:
Coronary Artery Disease
Myocardial Ischemia
Coronary Disease
Heart Diseases
Cardiovascular Diseases
Arteriosclerosis
Arterial Occlusive Diseases
Vascular Diseases